-
61.发明授权Methods of using biologically active dimerized polypeptide fusions to detect PDGF 失效使用生物活性二聚化多肽融合物检测PDGF的方法
公开(公告)号：US5567584A
公开(公告)日：1996-10-22
申请号：US180195
申请日：1994-01-11
IPC分类号： A61K38/00 , C07K14/71 , C07K16/18 , C12N15/62 , C12N15/67 , C12N15/81 , G01N33/566 , G01N33/68 , G01N33/74 , C12Q1/68
CPC分类号： C07K16/18 , C07K14/71 , C12N15/62 , C12N15/625 , C12N15/67 , C12N15/81 , G01N33/566 , G01N33/6863 , G01N33/74 , A61K38/00 , C07K2319/00 , C07K2319/02 , C07K2319/036 , C07K2319/32 , G01N2333/49 , G01N2333/71
摘要： Methods for producing secreted receptor analogs and biologically active peptide dimers are disclosed. The methods for producing secreted receptor analogs and biologically active peptide dimers utilize a DNA sequence encoding a receptor analog or a peptide requiring dimerization for biological activity joined to a dimerizing protein. The receptor analog includes a ligand-binding domain. Polypeptides comprising essentially the extracellular domain of a human PDGF receptor fused to dimerizing proteins, the portion being capable of binding human PDGF or an isoform thereof, are also disclosed. The polypeptides may be used within methods for determining the presence of and for purifying human PDGF or isoforms thereof.
摘要翻译： 公开了生产分泌的受体类似物和生物活性肽二聚体的方法。 用于产生分泌的受体类似物和生物活性肽二聚体的方法利用编码受体类似物的DNA序列或需要二聚化的肽连接到二聚化蛋白的生物活性。 受体类似物包括配体结合结构域。 还公开了包含与二聚化蛋白融合的人PDGF受体的基本上胞外结构域的多肽，该部分能够结合人PDGF或其同种型。 多肽可以用于确定人PDGF或其同种型的存在和用于纯化人PDGF或其同种型的方法。
-
62.发明授权Method of producing secreted receptor analogs and biologically active peptide dimers 失效产生分泌的受体类似物和生物活性肽二聚体的方法
公开(公告)号：US5155027A
公开(公告)日：1992-10-13
申请号：US347291
申请日：1989-05-02
IPC分类号： G01N33/566 , A61K38/00 , A61P9/10 , C07K1/22 , C07K14/00 , C07K14/37 , C07K14/41 , C07K14/705 , C07K14/71 , C07K16/00 , C07K16/18 , C07K19/00 , C12N15/09 , C12N15/62 , C12N15/67 , C12N15/81 , C12P21/00 , C12P21/02 , C12R1/19 , C12R1/865 , G01N33/68 , G01N33/74
CPC分类号： C07K14/71 , C07K16/18 , C12N15/62 , C12N15/625 , C12N15/67 , C12N15/81 , G01N33/6863 , G01N33/74 , A61K38/00 , C07K2319/00 , C07K2319/02 , C07K2319/036 , C07K2319/32 , G01N2333/49 , G01N2333/71
摘要： Methods for producing secreted receptor analogs and biologically active peptide dimers are disclosed. The methods for producing secreted receptor analogs and biologically active peptide dimers utilize a DNA sequence encoding a receptor analog or a peptide requiring dimerization for biological activity joined to a dimerizing protein. The receptor analog includes a ligand-binding domain. Polypeptides comprising essentially the extracellular domain of a human PDGF receptor fused to dimerizing proteins, the portion being capable of binding human PDGF or an isoform thereof, are also disclosed. The polypeptides may be used within methods for determining the presence of and for purifying human PDGF or isoforms thereof.
摘要翻译： 公开了生产分泌的受体类似物和生物活性肽二聚体的方法。 用于产生分泌的受体类似物和生物活性肽二聚体的方法利用编码受体类似物的DNA序列或需要二聚化的肽连接到二聚化蛋白的生物活性。 受体类似物包括配体结合结构域。 还公开了包含与二聚化蛋白融合的人PDGF受体的基本上胞外结构域的多肽，该部分能够结合人PDGF或其同种型。 多肽可以用于确定人PDGF或其同种型的存在和用于纯化人PDGF或其同种型的方法。
-
公开(公告)号：US4985541A
公开(公告)日：1991-01-15
申请号：US36840
申请日：1987-04-10
IPC分类号： A61K36/428 , A61K47/48
CPC分类号： A61K47/48469 , A61K36/428
摘要： Purified cytotoxic proteins for use within therapeutic compositions are disclosed. The proteins inhibit protein synthesis in vitro, exhibit abortifacient activity in mice, and contain proline residues with equivalent positions at residue 43 and residue 46 in ricin A-chain. A method for preparing such a cytotoxic protein from the tissue of Trichosanthes kirilowii is also disclosed. The proteins may also be used within a method for inhibiting protein synthesis in selected cells.
-
64.发明申请Compositions and methods including B lymphocyte cell line expressing membrane immunoglobulin different from secreted immunoglobulin 有权组成和方法，包括不同于分泌免疫球蛋白的B淋巴细胞细胞系表达膜免疫球蛋白公开(公告)号：US20130164277A1
公开(公告)日：2013-06-27
申请号：US13374353
申请日：2011-12-22
CPC分类号： A61K35/17 , A61K39/00 , A61K2039/5156 , A61K2039/6012 , A61K2039/6081 , C07K16/00 , C07K16/1018 , C07K16/109 , C07K16/1271 , C07K16/3069 , C07K16/40 , C07K16/44 , C07K2317/14 , C07K2317/622 , C07K2317/76 , C12N5/0635 , C12N2510/00
摘要： Compositions and methods are disclosed herein for producing one or more immunoglobulins in an isolated B lymphocyte cell line. An isolated recombinant cell line includes an isolated B lymphocyte cell line capable of expressing at least one endogenous membrane immunoglobulin reactive to a first antigen and at least one exogenously incorporated nucleic acid encoding at least one secreted immunoglobulin reactive to a second antigen.
摘要翻译： 本文公开了在分离的B淋巴细胞系中产生一种或多种免疫球蛋白的组合物和方法。 分离的重组细胞系包括能够表达至少一种对第一抗原具有活性的内源膜免疫球蛋白和至少一种外源掺入的编码至少一种与第二抗原反应的分泌的免疫球蛋白的分泌的免疫球蛋白的B淋巴细胞系。
-
公开(公告)号：US20130046555A1
公开(公告)日：2013-02-21
申请号：US13199038
申请日：2011-08-16
申请人： Roderick A. Hyde , Jordin T. Kare , Wayne R. Kindsvogel , Royce A. Levien , Erez Lieberman , Mark A. Malamud , Nathan P. Myhrvold , Elizabeth A. Sweeney , Clarence T. Tegreene , Charles Whitmer , Lowell L. Wood, JR.
发明人： Roderick A. Hyde , Jordin T. Kare , Wayne R. Kindsvogel , Royce A. Levien , Erez Lieberman , Mark A. Malamud , Nathan P. Myhrvold , Elizabeth A. Sweeney , Clarence T. Tegreene , Charles Whitmer , Lowell L. Wood, JR.
CPC分类号： G06Q50/22
摘要： Embodiments disclosed herein relate to methods, devices, and computer systems thereof for visibly or non-visibly indicating a subject has received a medical treatment. In certain embodiments, a subject receives an information mark in conjunction with a medical treatment. In certain embodiments, the information mark includes unique information relating to the subject. In certain embodiments, devices, computer systems, and methods relate to reading an information mark on a subject, and optionally determining if further medical treatment of the subject is warranted. In certain embodiments, receipt of an information mark entitles a subject to a reward.
-
公开(公告)号：US20120283143A1
公开(公告)日：2012-11-08
申请号：US13068304
申请日：2011-05-06
CPC分类号： C40B60/12
摘要： Embodiments disclosed herein relate to methodology, and kits thereof for identifying particular disease-associated antibodies partially based on comparative binding to a mimotope array. Isolation of identified disease-associated antibodies and uses thereof are also described.
摘要翻译： 本文公开的实施方案涉及部分基于与模拟表位阵列的比较结合来鉴定特定疾病相关抗体的方法及其试剂盒。 还描述了确定的疾病相关抗体的分离及其用途。
-
公开(公告)号：US20120283113A1
公开(公告)日：2012-11-08
申请号：US13068303
申请日：2011-05-06
CPC分类号： G01N33/6854 , G01N33/6845
摘要： Embodiments disclosed herein relate to methodology, and kits thereof for identifying particular disease-associated antibodies partially based on comparative binding to a mimotope array. Isolation of identified disease-associated antibodies and uses thereof are also described.
-
公开(公告)号：US20120282246A1
公开(公告)日：2012-11-08
申请号：US13068302
申请日：2011-05-06
IPC分类号： A61K39/395 , C12P21/00 , A61P37/04 , C12N5/0781 , A61P31/16 , C40B30/04 , C07K16/00
CPC分类号： C07K16/1018 , C07K16/18 , C07K16/3069 , C07K2317/10 , C40B30/04 , G01N33/56972 , G01N33/6845 , G01N33/6854
摘要： Embodiments disclosed herein relate to methodology, and kits thereof for identifying particular disease-associated antibodies partially based on comparative binding to a mimotope array. Isolation of identified disease-associated antibodies and uses thereof are also described.
-
69.发明授权Non-external static magnetic field imaging systems, devices, methods, and compositions 有权非外部静磁场成像系统，装置，方法和组合物公开(公告)号：US08154285B1
公开(公告)日：2012-04-10
申请号：US12455300
申请日：2009-05-29
IPC分类号： G01V3/00
CPC分类号： G01R33/5601 , G01R33/445
摘要： Magnetic resonance systems, devices, methods, and compositions are provided. Further provided are systems, devices, methods, and compositions for obtaining magnetic resonance information of a region within a biological subject without the need or use of an external-magnet.
摘要翻译： 提供了磁共振系统，装置，方法和组合物。 还提供了用于在不需要或使用外部磁体的情况下获得生物学对象内的区域的磁共振信息的系统，装置，方法和组合物。
-
70.发明申请公开(公告)号：US20110300098A1
公开(公告)日：2011-12-08
申请号：US12826099
申请日：2010-06-29
申请人： Wayne R. Kindsvogel , Steven D. Hughes , Richard D. Holly , Christopher H. Clegg , Donald C. Foster , Rebecca A. Johnson , Mark D. Heipel , Pallavur V. Sivakumar
发明人： Wayne R. Kindsvogel , Steven D. Hughes , Richard D. Holly , Christopher H. Clegg , Donald C. Foster , Rebecca A. Johnson , Mark D. Heipel , Pallavur V. Sivakumar
CPC分类号： C07K16/32 , A61K38/20 , A61K39/395 , A61K39/39558 , C07K16/2818 , C07K16/2896 , C07K2317/732 , A61K2300/00
摘要： Methods for treating cancer by co-administering a therapeutic monoclonal antibody with IL-21 are described. Exemplary monoclonal antibodies that can be used are rituximab, trastuzumab and anti-CTLA-4 antibodies. The enhanced antitumor of the combination therapy is particularly useful for patient populations that are recalcitrant to monoclonal therapy, relapse after treatment with monoclonal antibodies or where the enhanced IL-21 antitumor effect reduces toxicities associated with treatment using the monoclonal antibodies.
摘要翻译： 描述了通过用IL-21共同施用治疗性单克隆抗体来治疗癌症的方法。 可以使用的示例性单克隆抗体是利妥昔单抗，曲妥珠单抗和抗CTLA-4抗体。 联合治疗的增强的抗肿瘤剂对于单克隆治疗顽固性，用单克隆抗体治疗后复发或增强的IL-21抗肿瘤作用降低与使用单克隆抗体治疗相关的毒性的患者群体特别有用。
-
-
-
-
-
-
-
-
-
搜索结果
86 条记录 (耗时 0.061 秒)
